Add On Treatment for Cognitive Deficits in Schizophrenia
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study will look at the impact of dosing as well as ongoing treatment with an
investigation medication identified as PF-03654746, on cognitive and physiologic indicators
of brain function. Data from this study will assist with the evaluation of the utility of
functional magnetic resonance imaging, arterial spin labeling (ASL), and electrophysiologic
measures in the detection of early signals of the effectiveness of medications developed to
target cognitive impairment in schizophrenia. Safety and tolerability of PF-03654746 in this
population will be also be evaluated.